Press Release

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Pneumonia Treatment Market to Grow at a CAGR of 7.8% During 2022-2027, Aided by the Rising Prevalence of Pneumococcal Diseases Worldwide

According to a new report by EMR titled, ‘Global Pneumonia Treatment Market Report and Forecast 2022-2027’, the global market for pneumonia treatment attained a value of about USD 15.8 billion in 2020. The market is further expected to grow at a CAGR of 7.8% between 2022 and 2027.

The global pneumonia treatment industry is being driven by the heightened prevalence of pneumonia infections among young children worldwide. In addition, the rapidly ageing population, which is more susceptible to such infectious diseases, is leading to increased morbidity and mortality rates. As a result, vaccinations such as pneumococcal vaccines are increasingly being administered in the treatment and prevention of illnesses for patients with severe pneumonia cases. Moreover, governments are increasingly collaborating with international organisations to raise awareness about pneumonia among the masses, while ensuring the supply of required medicines in the affected areas. Furthermore, the world is witnessing a significant increase in pneumonia cases caused by COVID-19 with heightened mortality rates.

The rising emphasis of the leading players in the development of vaccines and antibiotics by utilising advanced clinical solutions is expected to positively impact the industry growth in the forecast period. In June 2021,  Pfizer Inc (NYSE: PFE) announced the reception of US FDA approval for their PREVNAR 20™ vaccine, which aims to prevent invasive diseases and pneumonia in adults of 18 years and above. In addition, another leading pharmaceutical manufacturer, GlaxoSmithKline (NYSE: GSK), in February 2021, announced their plans to conduct experimental tests of rheumatoid arthritis drug on patients suffering from pneumonia caused by COVID-19 with a special focus on the elderly, as an earlier study that tested the impact of otilimab medicine on elderly COVID patients showed a positive result. These developments are expected to positively impact the growth of the pneumonia treatment industry in the forecast period.

Market Breakup by Product and Region:

  • The market is divided based on product into drugs, vaccines, and oxygen therapy. Among these, drugs can be further divided by type into branded and generic. Out of these, the branded subtype can be further categorised, on the basis of medicine, into quinolones, aminopenicillins, macrolides, B-lactamase inhibitors, cephalosporins, tetracyclines, glycopeptide antibiotics, and carbapenems, among others. Meanwhile, the generic subtype can be further segregated, based on medicine, into quinolones, and macrolides, among others.
  • Region-wise, the global market for pneumonia can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

  • The global market for pneumonia is being driven by the increasing incidences of pneumonia worldwide. 
  • The rampant spread of the COVID-19 infection and a rise in the incidences of pneumonia caused by COVID are expected to significantly contribute to the market expansion.
  • The ageing population globally is also aiding the industry growth.
  • The rising technological advancements to develop improved treatments for pneumonia are further propelling the market growth.

Key Offerings of the Report:

  • The EMR report gives an overview of the global market for pneumonia treatment for the periods (2017-2021) and (2022-2027).
  • The report also offers historical (2017-2021) and forecast (2022-2027) market information for the products and major regions of pneumonia treatment.
  • The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global pneumonia treatment market are Pfizer Inc., Bayer AG, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, and Lupin Pharmaceuticals Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER